MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors and Leukemia

Trial Profile

MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors and Leukemia

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs Trametinib (Primary) ; Carboplatin; Docetaxel; Erlotinib; Everolimus; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Leukaemia; Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 19 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 19 Mar 2018 This trial has been completed in France according to European Clinical Trials Database record.
    • 10 Jan 2018 Planned End Date changed from 30 Nov 2017 to 30 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top